Atrasentan prolongs time to progression in prostate cancer patients.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077868:Atrasentan; D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000517:prevention & control* / Q000556:secondary; D018450:Disease Progression; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D011759:Pyrrolidines; D016032:Randomized Controlled Trials as Topic
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011759:Pyrrolidines; D000077868:Atrasentan